REPORT HIGHLIGHT
Calcium Channel Blockers Market size was valued at USD 14,005.1 Million in 2022, expanding at a CAGR of 6.1% from 2023 to 2030.
Calcium channel blockers are known as medications that are utilized to maintain high blood pressure, arrhythmia, and chest pain. Additionally, they can be obtained through prescription and work by relaxing blood vessels and improving the heart's blood and oxygen supply. As a result, this helps to minimize the workload of the heart. Moreover, to treat high blood pressure and angina, it may be prescribed by itself or in conjunction with other medications.
Calcium Channel Blockers Market- Market Dynamics:
- The increasing prevalence rate of cardiovascular diseases and rising assistance to people with anxiety disorders or bipolar disorder is projected to drive growth in the forecast period.
- The changing lifestyle of people has resulted in the increasing prevalence rate of cardiovascular diseases is likely to fuel the calcium channel blocker market growth. As these diseases impact the heart or blood vessels and lower the risk of heart failure & stroke, calcium channel blockers are used. Additionally, the major causes associated with heart disease are hypertension, often referred to as elevated blood pressure. The effectiveness of calcium antagonists in curing this indication has been well documented. This in turn, the demand has been growing steadily for this market for improved management of cardiovascular diseases. However, side effects concerning calcium channel blockers including headache, constipation, and edema are expected to hinder the demand for calcium channel blocker market globally. Moreover, calcium channel blockers may be advantageous to a smaller group of persons who do not have heart issues. In line with this, some indications they may act as mood stabilizers and assist those people who suffer from anxiety disorders or bipolar disorder. The latter is specifically under investigation because some calcium channel blockers may be more secure to administer to pregnant women as compared to most traditional mood stabilizers or antipsychotics. Thus, such factors offer opportunity to increase the growth of the calcium channel blocker market.
Calcium Channel Blockers Market- Key Insights:
- As per the analysis shared by our research analyst, the global calcium channel blocker market is estimated to grow annually at a CAGR of around 6.1% over the forecast period (2023-2030)
- The calcium channel blocker industry is projected to grow at a significant rate due to the increasing prevalence rate of cardiovascular diseases
- Based on drug class segmentation, dihydropyridine was predicted to show maximum market share in the year 2022
- Based on application segmentation, hypertension was the leading type over the forecast period
- On the basis of region, North America was the leading revenue generator in 2022
Calcium Channel Blockers Market- Segmentation Analysis:
- The global calcium channel blockers market is segmented on the basis of drug class, application, distribution channel, and region.
- The market is divided into three categories based on drug class: dihydropyridine, phenylalkylamine, and benzothizepine. The dihydropyridine segment is likely to possess the largest revenue share. The segment is anticipated due to the increasing research & development activities and expansion in the pharmaceutical industry. Moreover, the drug has great vascular selectivity and the capacity to control arterial pressure and vascular resistance, which is widely preferred in therapeutics. Dihydropyridine drugs include felodipine, amlodipine, nitrendipine, and nimodipine.
- The market is divided into four categories based on application: angina, hypertension, hypertrophic cardiomyopathy, arrhythmia, and others. The hypertension segment is expected to hold the largest market share. The hypertension segment raises the risk of heart, brain, and renal problems. Based on this, the demand is likely to increase for drugs used to manage hypertension.
- The market is divided into three categories based on distribution channels: online pharmacies, hospital pharmacies, and retail pharmacies. The retail pharmacies segment is accounted to dominate the market over the forecast period. The unhealthy lifestyle patterns have been resulting in increasing glowing obesity and cardiovascular diseases. As such drugs are prescribed on a regular basis to maintain the blood pressure. Additionally, rising cases of cardiovascular diseases such as congenital heart disease, heart failure, hypertension, and heart attacks are fueling the expansion of retail medicine owing to increase abundance and high consumption in the market.
Calcium Channel Blockers Market- Geographical Insights:
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Calcium Channel Blockers Market- Competitive Landscape:
The presence of local and global companies makes the calcium channel blocker market moderately competitive. The major players are focusing on numerous growth strategies such as collaborations, product launches, and acquisitions, which are contributing constantly to the growth of the calcium channel blocker globally. Moreover, with the increasing cases of cardiovascular disease across the world, key players are investing amounts to develop new therapeutics and sustain themselves in the market. The improved healthcare infrastructure is raising the demand for the calcium channel blocker. For instance, in February 2022, FDA approved CMP Pharma's Norliqva oral solution. Additionally, the solution helps to treat hypertension, to lower blood pressure in adults & children 6 years of age. Norliqva comes in 150 mL bottles, which have 36-month dating
Recent Developments:
For instance, in May 2021, Milestone Pharmaceuticals, Inc. a biopharmaceutical company released positive topline safety and efficacy data from the Etripamil Phase 3 RAPID clinical trial. Additionally, the company's investigational calcium channel blocker in patients with paroxysmal supraventricular tachycardia (PSVT).
Key features of the study:
- This proposed research study on calcium channel blockers market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year.
- The report provides the client the latest up-to-date and trending insights about the calcium channel blockers market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for calcium channel blockers market.
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the calcium channel blockers market.
- Impact of COVID-19 on calcium channel blockers market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on calcium channel blockers market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the calcium channel blockers market, we have also included competitive landscape and key innovator analysis for the calcium channel blockers market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants who will help users to understand their financial information and strategic initiatives of players operating in the calcium channel blockers market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global calcium channel blockers market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CALCIUM CHANNEL BLOCKERS MARKET KEY PLAYERS
- Bayer
- Sanofi
- Wyeth-Ayerst
- ClearSynth
- AbMole Bioscience
- Pfizer
- Lupin Pharmaceuticals, Inc.
- Searle
- Knoll Pharmaceuticals
- GlaxoSmithKline Plc.
- Aventis
- AstraZeneca
- Novartis
GLOBALCALCIUM CHANNEL BLOCKERS MARKET, BY DRUG CLASS
- Dihydropyridine
- Phenylalkylamine
- Benzothizepine
GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY APPLICATION
- Angina
- Hypertension
- Hypertrophic Cardiomyopathy
- Arrhythmia
- Others
GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY DISTRIBUTION CHANNEL
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA